

Fibromyalgia Treatment Market - 2024-2033

<https://marketpublishers.com/r/FC1D619CD655EN.html>

Date: February 2026

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: FC1D619CD655EN

Abstracts

The Fibromyalgia Treatment Market was valued at US\$ 2.83 billion in 2024 and is anticipated to reach US\$ 3.88 billion by 2033, at a CAGR of 0.042 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Fibromyalgia Treatment Market.

This report delivers a comprehensive overview of the Fibromyalgia Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Fibromyalgia Treatment Market. The Fibromyalgia Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Fibromyalgia Treatment Market Scope:

By Treatment Type

Analgesics

Antidepressants

Anti-Seizure Drugs

Therapies

By Route of Administration

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Eli Lilly and Company.

Pfizer Inc.

AbbVie.

Axsome Therapeutics, Inc.

Scilex Holding

GSK plc

Bayer AG

Teva Pharmaceuticals USA, Inc.

Johnson & Johnson

Tonix Pharmaceuticals Holding Corp.

Major Highlights

This report delivers a comprehensive overview of the Fibromyalgia Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Fibromyalgia Treatment Market. The Fibromyalgia Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Treatment Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Prevalence of Fibromyalgia
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Lack of Awareness among Individuals
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 5.1. Market Leaders and Pioneers
- 5.2. Emerging Pioneers and Prominent Players
- 5.3. Established leaders with largest largest-selling Brand
- 5.4. Market leaders with established Product
- 5.5. CXO Perspectives
- 5.6. Latest Developments and Breakthroughs
- 5.7. Case Studies/Ongoing Research
- 5.8. Regulatory and Reimbursement Landscape
- 5.9. North America
- 5.10. Europe

- 5.11. Asia Pacific
- 5.12. Latin America
- 5.13. Middle East & Africa
- 5.14. Porter's Five Force Analysis
- 5.15. Supply Chain Analysis
- 5.16. Patent Analysis
- 5.17. SWOT Analysis
- 5.18. Unmet Needs and Gaps
- 5.19. Recommended Strategies for Market Entry and Expansion
- 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 5.21. Pricing Analysis and Price Dynamics
- 5.22. Key Opinion Leaders

6. BY TREATMENT TYPE

- 6.1. Introduction
 - 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 6.1.2. Market Attractiveness Index, By Treatment Type
- 6.2. Analgesics*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 6.2.3. Acetaminophen
 - 6.2.4. Ibuprofen
 - 6.2.5. Naproxen Sodium
 - 6.2.6. Tramadol
 - 6.2.7. Others
- 6.3. Antidepressants
 - 6.3.1. Duloxetine
 - 6.3.2. Milnacipran
 - 6.3.3. Amitriptyline
 - 6.3.4. Others
- 6.4. Anti-Seizure Drugs
 - 6.4.1. Gabapentin
 - 6.4.2. Pregabalin
 - 6.4.3. Others
- 6.5. Therapies
 - 6.5.1. Physical therapy
 - 6.5.2. Cognitive Behavioral Therapies
 - 6.5.3. Acupuncture

6.5.4. Others

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

7.1.2. Market Attractiveness Index, By Route of Administration

7.2. Oral *

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Parenteral

8. BY DISTRIBUTION CHANNEL

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

8.1.2. Market Attractiveness Index, By Distribution Channel

8.2. Hospital Pharmacies*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacies

8.4. Online Pharmacies

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Spain

9.3.6.5. Italy

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Eli Lilly and Company. *

11.1.1. Company Overview

11.1.2. Product Portfolio

11.1.2.1. Product Description

11.1.2.2. Product Key Performance Indicators (KPIs)

11.1.2.3. Historic and Forecasted Product Sales

11.1.2.4. Product Sales Volume

11.1.3. Financial Overview

11.1.3.1. Company Revenue's

11.1.3.2. Geographical Revenue Shares

11.1.3.3. Revenue Forecasts

11.1.4. Key Developments

11.1.4.1. Mergers & Acquisitions

11.1.4.2. Key Product Development Activities

11.1.4.3. Regulatory Approvals etc.

11.1.5. SWOT Analysis

11.2. Pfizer Inc.

11.3. AbbVie.

11.4. Axsome Therapeutics, Inc.

11.5. Scilex Holding

11.6. GSK plc

11.7. Bayer AG

11.8. Teva Pharmaceuticals USA, Inc.

11.9. Johnson & Johnson

11.10. Tonix Pharmaceuticals Holding Corp. (LIST NOT EXHAUSTIVE*)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Fibromyalgia Treatment Market - 2024-2033

Product link: <https://marketpublishers.com/r/FC1D619CD655EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FC1D619CD655EN.html>